Skip to main content
OpenTrials
Completed

NCT Number: NCT05037526

Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care in Pregnancy Outcomes

Once a pregnant mother is diagnosed with gestational diabetes mellitus (GDM), she will be treated with either diet, medication (i.e., insulin), or both. The most important factor in GDM management is glycemic control to reduce adverse outcomes. Blood glucose levels have become the "key player" for monitoring and directing treatment during pregnancy. Large trials have confirmed that treatment of GDM to optimize glycemic control can decrease the incidence of many of these associated adverse maternal and neonatal outcomes. Up to now, SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily. However, SMBG provides an incomplete picture of the daily glucose profile due to long intervals between finger pricking, and inaccurate self-reported measurements, which heavily rely on patients' compliance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Bern, Inselspital

Bern, 3010, Switzerland

About this study

The incidence of obesity and diabetes is rising worldwide even in younger populations. With a rise in maternal obesity also gestational diabetes mellitus (GDM) becomes more prevalent with a prevalence of up to 18% of pregnancies. Up to now, SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily. The main purpose of this study is to prove that real time continuous glucose monitoring (rt-CGM) can effectively reduce the risk for adverse pregnancy and neonatal outcome in GDM. It is further hypothesized that rt-CGM can optimize maternal glycaemic control, increase patients satisfaction and adherence to management strategies of GDM. This is a open label randomized controlled trial with two parallel groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed Consent as documented by signature
  • GDM diagnosis between 24 0/7- 28 0/7 weeks of pregnancy by a 75g oral glucose test (oGTT)
  • Maternal age of 18 to 45 years,
  • Singleton gestation
  • Gestational age ≥ 24 0/7 weeks and <32 0/7 weeks at enrollment.

Exclusion criteria

  • Known hypersensitivity or allergy to the sensor
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders of the participant
  • Participation in another study with investigational drug or product within the 30 days preceding and during the present study
  • Maternal age < 18 years,
  • Multi-fetal gestations,
  • Known fetal structural or chromosomal anomalies
  • Chronic use of medications associated with hyperglycemia (steroids)
  • Planned preterm delivery
  • Overt diabetes mellitus type 1 or 2
  • HbA1c by study entry > 6.5%
  • History of bariatric surgery or other surgeries that induce malabsorption
  • Fetal growth restriction by study entry

Treatment and study plan

Dexcom G System

Device

Continuous glucose monitoring system

Self Monitoring Blood Glucose

Device

Standard Care

Primary outcomes

  1. Composite adverse pregnancy and neonatal outcome

    Time frame: 2 years

    The primary endpoint is composite adverse pregnancy and neonatal outcome; the proportion of large for gestation age (LGA) newborns (birth weight >90th centile); fetal macrosomia (estimated fetal weight over the 95th centile); incidence of polyhydramnios (maximal vertical pocket ≥ 8 cm); rate of neonatal hypoglycaemia; occurrence of stillbirth. Every each and one of these variables contributes to a better neonatal outcome and are associated. This composite endpoint includes factors influencing decisive the neonatal outcome.

Secondary outcomes

  1. Initiated Therapy

    Time frame: 10-14 weeks

    Need for antiglycemic therapy in example Insulin yes/no

  2. Glycemic Outcomes 1

    Time frame: 10-14 weeks

    Glycemic variability including number and duration of hypoglycemic and hyperglycemic events, mean interstitial glucose in mmol/L and its standard deviation (SD) A hypoglycemic event was defined for two separate analyses as excursions of at least 15 min below the target range (<3.5 mmol/L), and a hyperglycemic event was defined for two separate analyses as excursions of at least 15 min above the target range (>7.8 mmol/L).

  3. Glycemic Outcomes 2

    Time frame: 10-14 weeks

    Time in glucose target in %

  4. Glycemic Outcomes 3

    Time frame: 10-14 weeks

    Duration and frequency postprandial hyperglycaemic excursions

  5. Glycemic Outcomes 4

    Time frame: 10-14 weeks

    Hemoglobin A1c (HbA1c) values (at inclusion, birth and postpartum) in %

  6. Pregnancy complications

    Time frame: 10-14 weeks

    Pregnancy Complications such as

    • Placenta insufficiency (Estimated fetal weight < 10th centile and blood flow changes),
    • Gestational hypertension (systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mg Hg on two occasions at least 4 hours apart)
    • Preeclampsia (international Society for the Study of Hypertension in Pregnancy (ISSHP) definition)
  7. Mode of Delivery

    Time frame: 10-14 weeks

    Mode of delivery including cesarean delivery, induction of labor, need for operative vaginal delivery (forceps or vacuum-assisted vaginal delivery)

  8. Need for induction of labor

    Time frame: 10-14 weeks

    Induction of labor yes/no

  9. Obstetrical outcome

    Time frame: 10-14 weeks

    Obstetric injury yes/no

  10. Maternal outcomes

    Time frame: 10-14 weeks

    Body mass index (BMI) (pre-pregnancy and at the time of delivery) weight and height will be combined to report BMI in kg/m^2

  11. Maternal weight gain

    Time frame: 10-14 weeks

    Weight gain after GDM diagnosis in kg

  12. Maternal Compliance

    Time frame: 10-14 weeks

    Adherence to therapy yes/no

  13. Maternal satisfaction questionnaire

    Time frame: 10-14 weeks

    Patient satisfaction after pregnancy evaluated through a questionnaire

  14. Postpartum disorder

    Time frame: 10-14 weeks

    8 weeks postpartum oral glucose test values in mmol/L

  15. Birth age

    Time frame: 10-14 weeks

    Gestational age at delivery in weeks

  16. Preterm

    Time frame: 10-14 weeks

    Preterm delivery (delivery < 37 weeks gestational age) yes/no

  17. Neonatal weight

    Time frame: 10-14 weeks

    Birth weight in grams

  18. Neonatal outcome

    Time frame: 10-14 weeks

    Small for gestational age (birth weight < 10%) yes/no

  19. Neonatal condition

    Time frame: 10-14 weeks

    Poor condition at birth (Apgar score at 5 minutes <7, Arterial pH of <7.0) yes/no

  20. Neonatal Morbidity

    Time frame: 10-14 weeks

    Perinatal morbidity prior to hospital discharge.

  21. Neonatal birth trauma

    Time frame: 10-14 weeks

    Birth trauma (brachial plexus injury, or clavicular, humeral, or skull fracture)

  22. Resuscitation

    Time frame: 10-14 weeks

    Need for resuscitation yes/no

  23. Neonatal Care

    Time frame: 10-14 weeks

    Admission to neonatal intensive care unit (NICU) with length of stay in days

  24. Respiratory distress syndrome

    Time frame: 10-14 weeks

    Respiratory distress syndrome (need for supplemental oxygen > 4 hours after birth) yes/no

Sponsors and collaborators

Lead sponsor

Insel Gruppe AG, University Hospital Bern

Other

Registry information

Official study title

Diabetes in Pregnancy Project Und Mobile Health in Gestational Diabetes: An Open Label Randomized Controlled Monocentric Trial on the Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care

Acronym: DiP GlucoMo

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Sep 8, 2021
Registry last updated
Dec 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.